Our findings implicate DDX3X as an Xi-expressed driver of female-biased anti-tumorigenic IFN activity in TAM-MGs, and thus, better GBM outcomes in females compared to males (Fig. 4H). This evidence concerns the gene DDX3X and glioblastoma.